Aetna Noninvasive Positive Pressure Ventilation Coverage

inv-01: Restrictive Thoracic Disorders

Covered when ALL of the following are met:

Restrictive criteria: 1. COPD does not contribute significantly to the member's pulmonary limitation; 2. Member has a progressive neuromuscular disease or severe thoracic cage abnormality; 3. Member has symptoms of sleep-associated hypoventilation (e.g., daytime hypersomnolence, excessive fatigue, dyspnea, morning headache, cognitive dysfunction); 4. Member has clinically significant hypoxemia as indicated by ANY of: (a) awake arterial PaCO2 >= 45 mm Hg while breathing usual FiO2; OR (b) sleep oximetry showing SpO2 <= 88% for >= 5 minutes of nocturnal recording time (minimum recording time 2 hours) while breathing usual FiO2; OR (c) for progressive neuromuscular disease only, maximal inspiratory pressure < 60 cm H2O or FVC < 50% predicted.PaCO2 >= 45 mm Hg; SpO2 <= 88% >=5 minutes; MIP <60 cm H2O or FVC <50% for neuromuscular

From policy section: Restrictive Thoracic Disorders.

inv-02: Severe COPD

Covered when ALL of the following are met:

Severe COPD criteria: 1. Member has symptoms of sleep-associated hypoventilation (e.g., daytime hypersomnolence, excessive fatigue, dyspnea, morning headache, cognitive dysfunction); 2. Awake arterial blood gas PaCO2 >= 52 mm Hg; 3. Sleep oximetry demonstrates SpO2 <= 88% for >= 5 cumulative minutes of nocturnal recording time (minimum 2 hours) while breathing oxygen at 2 LPM or the member's prescribed FiO2 (whichever is higher); 4. Obstructive sleep apnea (OSA) has been considered and ruled out (formal sleep testing not required if medical record documents OSA is not the predominant cause of hypercapnia/desaturation).PaCO2 >= 52 mm Hg; SpO2 <=88% >=5 minutes

Bilevel PAP without backup considered medically necessary; backup-rate device allowed only per defined step-up criteria.

Situations permitting backup-rate bilevel for COPD: A backup-rate bilevel PAP device may be considered MEDICALLY NECESSARY in EITHER of the following: (A) At any time after initial use of a non-backup bilevel device when awake PaCO2 worsens by >= 7 mm Hg compared to the original qualifying result AND a facility PSG on the non-backup device shows SpO2 <=88% for >=5 minutes with AHI <5; OR (B) After >=60 days (2 months) of compliant use (average >=4 hours/day) of a non-backup bilevel device AND awake PaCO2 remains >=52 mm Hg AND sleep oximetry on the non-backup device demonstrates SpO2 <=88% for >=5 minutes while on oxygen or prescribed FiO2.

Step-up/upgrade logic for COPD.

inv-03: Central Sleep Apnea (CSA) / Complex Sleep Apnea (CompSA)

Covered when ALL of the following are met:

CSA/CompSA criteria: 1. A complete inpatient attended polysomnogram documents the diagnosis of central sleep apnea (CSA) or complex sleep apnea (CompSA) per policy Appendix/Glossary; AND 2. Demonstrated significant improvement in sleep-associated hypoventilation with a bilevel PAP device (with or without backup) on the settings to be prescribed for home use while the member breathes their prescribed FiO2.

Facility-based diagnostic PSG required prior to initiating therapy.

inv-04: Hypoventilation Syndrome

Covered when EITHER bilevel device without backup OR with backup is supported by criteria:

Bilevel without backup: Required: (i) Initial awake arterial PaCO2 >= 45 mm Hg while breathing the member's prescribed FiO2; AND (ii) Spirometry with FEV1/FVC >= 70%; AND either (iii) Awake or sleep PaCO2 worsened by >= 7 mm Hg from baseline OR (iv) PSG/HST demonstrates SpO2 <= 88% for >=5 minutes of nocturnal recording time (minimum 2 hours) that is not caused by obstructive events (AHI <5).

Criteria i and ii plus (iii or iv).

Bilevel with backup: Required for upgrade: (i) Member is using a medically necessary bilevel PAP device without a backup rate feature; AND (ii) Spirometry with FEV1/FVC >= 70%; AND either (iii) Awake PaCO2 worsens >= 7 mm Hg compared to the qualifying arterial blood gas used for initial device qualification OR (iv) PSG/HST performed on the non-backup device demonstrates SpO2 <= 88% for >=5 minutes (AHI <5).

Upgrade pathway when criteria met while on non-backup device.

inv-05: Obstructive Sleep Apnea (OSA)

Covered when BOTH of the following are met:

OSA criteria for bilevel without backup: 1. Member meets CPAP criteria as specified in CPB 0004 (adults) or CPB 0752 (children); AND 2. Member has had a trial of CPAP which was ineffective or not tolerated.

Backup-rate feature has no proven value for primary OSA and is considered experimental/investigational.

inv-06: Ventilators with Noninvasive Interfaces

Covered when ALL of the following are met:

Ventilator coverage: 1. Member has severe neuromuscular disease, thoracic restrictive disease, or chronic respiratory failure consequent to COPD where interruption or failure of respiratory support would lead to death; AND 2. Ventilator with noninvasive interface is selected because the severity/risk profile indicates interruption of support could be life-threatening; AND 3. Choice of ventilator versus bilevel PAP is based on the severity and CMS distinctions between ventilators and bilevel PAP devices.

Aetna follows CMS policy on ventilators with noninvasive interfaces; ventilators are not medically necessary for conditions appropriately managed with intermittent bilevel PAP.

inv-07: Second Respiratory Assist Device

Covered when device is required to serve a different purpose:

Examples: Covered when an individual requires two respiratory assist devices to serve different purposes (e.g., a wheelchair-mounted device for daytime use and a separate device for use in bed) and both are medically necessary to achieve appropriate medical outcomes; documentation must support distinct purposes of each device.

Examples in policy are illustrative, not exhaustive.

inv-08: Experimental and Investigational (Not Covered)

The following are considered experimental/investigational and not medically necessary:

Experimental indications: NPPV for indications not listed as medically necessary including: acute lung injury; as an alternative to endotracheal intubation following esophagectomy; asthma; bronchiolitis in infants/children; pneumonia; prevention of complications after pulmonary resection for lung cancer; use of exsufflation belt (intermittent abdominal daytime pressure ventilator) for pulmonary restrictive or obstructive breathing; single-breath tests for determining airway closure volume.

Policy lists examples where effectiveness has not been established.

inv-09: Continued Coverage Criteria Beyond First Three Months

Covered if ALL of the following are documented:

Continued coverage: 1. Re-evaluation after 2–3 months of therapy to assess continued medical necessity; 2. Documentation of compliant device use (average >= 4 hours per 24-hour period); 3. Documentation that the member is benefiting from use of NPPV (clinical improvement as recorded by the treating physician).

Either heated or non-heated humidifier is considered medically necessary with NPPV.

inv-10: NPPV for restrictive thoracic/neuromuscular disease

Covered when ALL of the following are met

Restrictive thoracic / neuromuscular indications: 1. Symptoms attributable to nocturnal hypoventilation (eg, daytime hypersomnolence, excessive fatigue, morning headache, cognitive dysfunction, dyspnea); AND 2. Objective physiologic finding of either awake PaCO2 >= 45 mm Hg OR nocturnal oxyhemoglobin desaturation defined as SpO2 <= 88% for >= 5 minutes.PaCO2 >= 45 mm Hg; SpO2 <=88% >=5 minutes

Consensus conference recommended these as sufficient indications; physician reassessment within 60 days recommended.

inv-11: NPPV for COPD (selective)

Covered when ALL of the following are met (COPD/highly selected patients)

Stable hypercapnic COPD - selective criteria: 1. Patient has substantial daytime CO2 retention and/or nocturnal oxygen desaturation (e.g., baseline PaCO2 >= 55 mm Hg associated with greater likelihood of benefit); AND 2. NPPV is delivered with adequate settings (e.g., IPAP >= 18 cm H2O where applicable) and adherence (use >= 5 hours/night); AND 3. Patient selection and device settings align with trial evidence showing benefit in selected hypercapnic COPD populations.PaCO2 >=55 mm Hg associated with benefit; IPAP >=18 cm H2O; usage >=5 h/night

Evidence mixed — LTHNIPPV meta-analyses show mortality reduction in selected patients but routine use in all stable COPD patients not supported.

inv-12: NPPV for other nocturnal hypoventilation syndromes

Covered when ALL of the following are met (other nocturnal hypoventilation syndromes)

Other disorders with nocturnal hypoventilation: 1. Disease known to cause hypoventilation; AND 2. Symptoms/signs of hypoventilation; AND 3. Failure of first-line therapies for mild cases (e.g., bronchodilators, respiratory stimulants, weight loss, supplemental oxygen, CPAP) OR presence of moderate-to-severe hypoventilation; AND 4. When sleep apnea is suspected, diagnostic polysomnogram is required and a CPAP trial is recommended if OSA is documented unless prior CPAP trial unsuccessful.

Polysomnogram required for diagnosis of sleep apnea; CPAP trial recommended before NPPV if OSA documented.

inv-13: NPPV for AHRF / post-extubation

Not routinely covered / use is conditional

Acute hypoxemic respiratory failure / post-extubation: Routine use of NPPV for all patients with acute hypoxemic respiratory failure (AHRF) or unselected post-extubation respiratory failure is not supported; effectiveness varies by population and trial heterogeneity. Selected patients may benefit in some trials, but evidence does not support universal application.

Some RCTs show reduced intubation in selected groups but mortality benefit is unclear; not routine.

inv-14: NPPV for tracheomalacia and upper airway obstruction

Covered as supportive/temporary therapy in specific airway disorders

Tracheomalacia and upper airway obstruction: 1. Short-term use of CPAP or NIPPV may be used to minimize airway collapse and reduce respiratory effort in infants and adults with tracheomalacia or related upper airway obstruction; AND 2. In very severe cases, invasive procedures (aortopexy, tracheostomy, stent placement) are preferred; AND 3. Evidence for long-term benefit on dyspnea/cough is limited and RCT data are lacking.

CPAP can 'stent' the airway open and may be used acutely or intermittently; invasive procedures reserved for severe cases.

inv-15: Contexts with evidence or discussion

Clinical contexts where NPPV has evidence or discussion in this excerpt

Acute respiratory failure - evidence: Strong RCT evidence supports NIV for acute respiratory failure in COPD and cardiogenic pulmonary edema; RCT-level evidence is weak or lacking for other groups (e.g., asthma, pneumonia, acute lung injury, immunocompromised).

Keenan & Mehta summary.

Postoperative ARF after upper abdominal surgery: CPAP or bi-level NPPV may reduce tracheal intubation rates and ICU length of stay versus oxygen therapy in selected trials (2 trials, 269 participants), but overall evidence quality is low to very low and further studies are needed.

Cochrane review findings.

Neonatal NIPPV vs NCPAP: Early NIPPV did not significantly decrease need for mechanical ventilation in first 72 hours versus NCPAP overall; some post-hoc analyses suggested benefit in subgroups (e.g., surfactant-treated infants).

Meneses et al RCT (200 infants).

inv-16: Evidence-based stance by indication

Evidence summaries and conclusions for specific indications in this excerpt:

Heart failure (HF): Small trials and meta-analyses indicate BiPAP/NIV may improve exercise tolerance (6MWT), dyspnea, LVEF and reduce BNP acutely; however, compliance, durability of effect, and mortality benefit are uncertain and NPPV is not a standard heart failure therapy in major guidelines.

Gomes Neto trial and Jiang meta-analysis.

Pediatric bronchiolitis: Large observational data show higher subsequent invasive mechanical ventilation after initial NPPV compared with high-flow nasal cannula (20.1% vs 11.0%); adjusted OR 1.53 (95% CI 1.24–1.88), suggesting need for prospective trials before routine use.

Clayton et al multicenter study.

Prevention of post-op pulmonary complications after lung resection: Systematic review (7 RCTs + 1 quasi-RCT; 486 patients) found no difference between NIPPV and control for pulmonary complications, intubation, mortality, ICU/hospital length of stay, or adverse events; evidence quality low to very low and guidelines do not recommend routine postoperative NIPPV.

Cochrane/systematic review findings; ERAS/ESTS guidance.

The policy lists specific uses of noninvasive positive pressure ventilation (NPPV) that are considered experimental/investigational and not medically necessary because effectiveness has not been established. Examples explicitly named include NPPV for acute lung injury, as an alternative to endotracheal intubation following esophagectomy, asthma, bronchiolitis in infants and children, pneumonia, and prevention of complications after pulmonary resection for lung cancer. The policy also states that the evidence does not support routine use of single-breath tests for airway closure volume in clinical management.

NPPV is generally not indicated for patients who are unable to cooperate with mask-based therapy or for those who require a protected airway to manage excessive secretions. In such situations (for example, impaired ability to protect the upper airway), the policy indicates that invasive airway management such as tracheostomy is usually preferred and requests for NPPV in these circumstances may be denied.

For patients with progressive neuromuscular disease, the policy highlights objective physiologic markers (e.g., FVC <50% predicted or MIP <60 cm H2O) as part of assessing need for NPPV, emphasizing that inability to cooperate or protect the airway remains a coverage-limiting contraindication.

The policy notes that randomized controlled trial (RCT) evidence is strong for NIV in acute respiratory failure from COPD and cardiogenic pulmonary edema but is lacking or inconclusive for many other etiologies such as asthma, pneumonia, and acute lung injury. This lack of RCT-level support is cited as a rationale for considering NPPV experimental for those indications.

Regarding diagnostic testing, the policy summarizes evidence and guidance that the single-breath nitrogen test (SBNT) has limited clinical value: multiple studies and ATS guidance found SBNT variables less reproducible and not helpful for identifying persons at risk for developing COPD compared with spirometry.

The policy states that routine postoperative use of noninvasive positive pressure ventilation after pulmonary resection is not supported by current evidence. A systematic review of trials following lung resection found no additional benefit of NIPPV for pulmonary complications, intubation rate, mortality, or length of stay, and international ERAS/ESTS guidance concludes that routine postoperative NIPPV cannot be recommended.

Similarly, trials of NPPV for respiratory failure after extubation or for unselected acute hypoxemic respiratory failure have produced heterogeneous results; the policy therefore indicates that NPPV is not routinely covered in these postoperative/acute hypoxemic contexts and use should be limited to selected patients where trial evidence or physiologic response supports benefit.

This Clinical Policy Bulletin is intended to assist in administering plan benefits and does not constitute a guarantee of coverage or medical advice. Plan or program benefit documents govern payment, and the bulletin provides guidance to support clinical review; providers must confirm member-specific coverage and prior authorization requirements with the applicable plan documents.

The policy distinguishes between bilevel PAP devices and ventilators with noninvasive interfaces. Ventilators are reserved for severe neuromuscular disease, thoracic restrictive disease, or chronic respiratory failure where interruption of respiratory support could lead to death. Conversely, bilevel PAP devices are appropriate for intermittent support scenarios where interruption would not be imminently life-threatening. Use of a ventilator when a bilevel PAP device would appropriately manage the condition is considered not medically necessary.

The policy identifies specific HCPCS items that are not covered for indications in the bulletin. In particular, the exsufflation belt (HCPCS A4468) is listed as not covered for pulmonary restrictive or obstructive breathing indications.

The policy does not support routine application of NPPV for unselected patients with stable COPD or for all patients with acute hypoxemic respiratory failure. Historical trials and systematic reviews indicate benefit is confined to selected subgroups (e.g., COPD patients with significant daytime hypercapnia), and routine use in unselected populations is not supported.

The policy summarizes limitations of the single-breath nitrogen test (SBNT). Multiple empirical studies and ATS guidance conclude that SBNT has limited clinical value, poor reproducibility, and does not reliably predict progression to airflow obstruction compared with spirometry; therefore SBNT is considered investigational for airway-closure testing.

While the policy lists trials and systematic reviews regarding postoperative NIPPV, it does not make a blanket not-medically-necessary statement in every postoperative situation. Instead, the document reports that systematic reviews of lung resection trials found no consistent clinical benefit from postoperative NIPPV and that major ERAS/ESTS guidance does not recommend routine postoperative NIPPV — i.e., the evidence does not support routine use after lung surgery.

The policy references covered CPT/HCPCS codes that apply when selection criteria are met (for example, E0470, E0471, E0465–E0467, and E0601 for CPAP/BiPAP/ventilator devices) and accessory/mask codes (A70xx series). It also lists related polysomnography and oximetry CPT codes. Providers should bill the appropriate code only when device selection and clinical documentation meet the policy’s medical necessity criteria.

Coding and Billing

Covered CPT CodesCPTCovered

94002	Ventilation assist and management, initiation of pressure or volume preset ventilators for assisted or controlled breathing; hospital/clinic/physician
94003	Ventilation assist and management, subsequent care
94004	Ventilation assist and management, discharge management
94660	Continuous positive airway pressure ventilation (CPAP), initiation and management

Related / Diagnostic CPT Codes (neutral)CPT

94726	Plethysmography for determination of lung volumes and, when performed, airway resistance
82800	Gases, blood
82805	Carbon dioxide (e.g., PaCO2) - specific codes vary
94760	Noninvasive ear or pulse oximetry for oxygen saturation
94761	...
94762	...
95782	Polysomnography; younger than 6 years, sleep staging with 4 or more additional parameters, attended
95783	Polysomnography; younger than 6 years with initiation of CPAP or bilevel ventilation, attended
95808	Polysomnography; with minimum parameters
95810	Polysomnography with additional parameters

1–10 of 11

1/2

Covered HCPCS CodesHCPCSCovered

A7027	Combination oral/nasal mask, used with continuous positive airway pressure device
A7028	Oral cushion for combination oral/nasal mask, replacement only, each
A7029	Nasal pillows for combination oral/nasal mask, replacement only, pair
A7030	Full face mask, each
A7031	Face mask interface replacement, each
A7032	Replacement cushion for nasal application, each
A7033	Replacement pillows, pair
A7034	Nasal interface (mask or cannula type), with or without headstrap
A7044	Oral interface used with positive airway pressure device, each
A7045	Exhalation port with or without swivel used with accessories for positive airway devices, replacement only

1–10 of 19

1/2

HCPCS Not Covered for CPB IndicationsHCPCSNot Covered

A4468

Exsufflation belt, includes all supplies and accessories

Covered ICD-10 Codes (when selection criteria met)ICD-10Covered

B91	Sequelae of poliomyelitis
E66.2	Morbid (severe) obesity with alveolar hypoventilation
G12.0	Spinal muscular atrophy
G12.9	Spinal muscular atrophy, unspecified
G14	Postpolio syndrome
G47.31	Primary central sleep apnea
G47.33	Obstructive sleep apnea
G47.35	Congenital central alveolar hypoventilation syndrome
G47.36	Sleep related hypoventilation in conditions classified elsewhere
G47.37	Central sleep apnea in conditions classified elsewhere

1–10 of 35

1/4

ICD-10 Codes Referenced (covered)ICD-10Covered

E66.2	Morbid (severe) obesity with alveolar hypoventilation
G47.31	Primary central sleep apnea
G47.33	Obstructive sleep apnea
G47.35	Congenital central alveolar hypoventilation syndrome
G47.36	Sleep related hypoventilation in conditions classified elsewhere
G47.37	Central sleep apnea in conditions classified elsewhere
J44.9	Chronic lower respiratory disease (COPD)
J96.00	Acute respiratory failure, unspecified
R09.02	Hypoxemia
R06.00	Abnormalities of breathing

Example ICD-10 codes mentionedICD-10

G12.0	Spinal muscular atrophy and related syndromes
B91	Sequelae of poliomyelitis
M41.9	Scoliosis, unspecified
Q32.0	Congenital tracheomalacia
J80	Acute respiratory distress syndrome

Additional CPT/HCPCS/Other Codes Mentionedmixed

82800-82810	Blood gases and related assays
94760-94762	Pulse oximetry
95782-95783	Pediatric polysomnography codes
95808-95811	Polysomnography codes
94002-94004	Ventilation assist and management codes

Usual Medically Necessary Quantities of Supplies for Use With a NPPV (typical intervals)HCPCS

Tubing with integrated heating element	Quantity usually medically necessary = 1 per 3 months
Combination oral/nasal mask	Quantity usually medically necessary = 1 per 3 months
Oral cushion for combination oral/nasal mask	Quantity usually medically necessary = 2 per 1 month
Nasal pillows (pair)	Quantity usually medically necessary = 2 per 1 month
Full face mask	Quantity usually medically necessary = 1 per 3 months
Replacement face mask interface for full face mask	Quantity usually medically necessary = 1 per 1 month
Cushion for nasal mask	Quantity usually medically necessary = 2 per 1 month
Pillow for nasal cannula-type interface (pair)	Quantity usually medically necessary = 2 per 1 month
Nasal interface (mask or cannula)	Quantity usually medically necessary = 1 per 3 months
Headgear	Quantity usually medically necessary = 1 per 6 months

1–10 of 15

1/2

Arterial blood gas PaCO2 thresholds — numeric thresholds by pathway

Arterial blood gas PaCO2 thresholds — restrictive thoracic disorders>= 45 mm Hg

Arterial blood gas PaCO2 thresholds — COPD initial>= 52 mm Hg

Arterial blood gas PaCO2 worsening threshold for backup rate considerationIncrease >= 7 mm Hg from baseline

Nocturnal oxygen saturation — clinically significant hypoxemia<= 88% for >= 5 minutes (minimum recording time 2 hours)

Spirometry threshold (hypoventilation pathway)FEV1/FVC >= 70%

Maximal inspiratory pressure / FVC for neuromuscular diseaseMIP < 60 cm H2O or FVC < 50% predicted

Nocturnal oxygen saturation — threshold for clinically significant nocturnal hypoxemia

Nocturnal oxygen saturation threshold<= 88% for >= 5 minutes (minimum recording time 2 hours)

AHI requirement when hypoxemia not caused by obstructive eventsAHI < 5 to indicate non-obstructive cause

Spirometry threshold — FEV1/FVC criterion referenced for hypoventilation pathway

Spirometry thresholdFEV1/FVC >= 70%

Maximal inspiratory pressure / FVC for neuromuscular disease — MIP and FVC thresholds

Maximal inspiratory pressure (MIP)< 60 cm H2O (for progressive neuromuscular disease)

Forced vital capacity (FVC)< 50% predicted (for progressive neuromuscular disease)

PaCO2 key value

PaCO2 key value>= 52 mm Hg (COPD subgroup baseline)

Nocturnal oxyhemoglobin saturation key value

Nocturnal oxyhemoglobin saturation key value<= 88% for >= 5 minutes (minimum recording time 2 hours)

Baseline PaCO2 (COPD subgroup) — threshold associated with benefit

Baseline PaCO2 (COPD subgroup)>= 55 mm Hg associated with greater benefit in some studies

PaO2 improvement after bi-level NPPV — trial result metric

PaO2 improvement after bi-level NPPVMean difference +22.5 mm Hg at 1 hour in one small trial

Minimum events for AHI/CAHI if <2 hours of sleep — diagnostic threshold

Minimum events for AHI/CAHI if <2 hours of sleep>= 10 events

Provider Actions, Prior Authorization, and Documentation

Prior Authorization

Device selection must meet clinical criteria

Device selection must match the clinical indication. Choose the specific NPPV device type (CPAP, bilevel PAP without backup, bilevel PAP with backup rate, or ventilator with noninvasive interface) that corresponds to the member’s diagnosis and physiologic findings; document why the selected device is appropriate for the condition.

Select bilevel PAP without backup for OSA when CPAP criteria met and CPAP is not tolerated; backup rate devices are not covered for primary OSA.
For COPD, prefer bilevel PAP without backup initially; backup rate allowed only per specified worsening criteria or after trial and reassessment.

Documentation Required

Objective physiologic criteria required

Objective physiologic criteria are required to establish medical necessity. Document awake arterial blood gas PaCO2 values, sleep oximetry/PSG oxygen saturation results, and pulmonary function measures (FVC, FEV1/FVC, or maximal inspiratory pressure) as applicable to the diagnosis.

Hypoventilation / restrictive disorders: awake PaCO2 ≥45 mm Hg OR nocturnal SpO2 ≤88% for ≥5 minutes (minimum 2 hours recording) OR in progressive neuromuscular disease MIP <60 cm H2O or FVC <50% predicted.
Severe COPD: awake PaCO2 ≥52 mm Hg AND nocturnal SpO2 ≤88% for ≥5 cumulative minutes on oxygen at 2 LPM or prescribed FIO2 (minimum 2 hours).

Prior Authorization

Prior authorization — OHS and PAP therapy

Prior authorization is required for obesity hypoventilation syndrome (OHS) and for PAP therapy when required by plan. Provide documentation of diagnosis, prior trials (CPAP vs bilevel, supplemental oxygen trials), and physiologic data supporting selection of device and settings.

For OHS: document whether CPAP was tried first (when OSA present) and results; if CPAP insufficient, document step-up to bilevel/BPAP.
For CSA/CompSA: facility-based attended PSG documenting diagnosis and improvement on the prescribed bilevel settings is required prior to home therapy.

Billing Rule

Supply quantity limits

Supply quantity limits follow usual medically necessary quantities. Provide supply ordering consistent with the policy’s usual medically necessary frequency to avoid denials for over-supply.

Tubing with integrated heating element: 1 per 3 months.
Combination oral/nasal mask: 1 per 3 months; oral cushion: 2 per month; nasal pillows (pair): 2 per month; full face mask: 1 per 3 months; replacement cushions: 1 per month; headgear: 1 per 6 months; filters (disposable): 2 per month; water chamber: 1 per 6 months.

Prior Authorization

Confirm prior authorization with plan

Confirm prior authorization and coverage details with the member’s plan and benefit documents. Clinical policy criteria guide medical necessity determinations but do not supersede contract or benefit limitations; plan-level requirements govern payment and prior authorization processes.

Clinical policy does not equal plan benefits — verify coverage, prior authorization portals, and applicable exclusions before ordering.
Refer to plan documents for limits on device types, replacements, and supplier billing rules.

Denial Risk

Denial triggers for experimental indications

Denials may occur for experimental, investigational, or unproven indications. Do not request NPPV for diagnoses listed as experimental/investigational in the policy unless supporting high-quality evidence is provided and plan allows.

Examples of indications considered experimental/investigational: acute lung injury, asthma, bronchiolitis in infants/children, pneumonia for routine NPPV, use as alternative to intubation post-esophagectomy, prevention after pulmonary resection, exsufflation belt for pulmonary restrictive/obstructive breathing.

Denial Risk

Contraindications impacting coverage

Contraindications that may preclude coverage should be documented. Patients unable to cooperate with NPPV, those who require a protected airway, or those with excessive secretions not manageable with noninvasive interfaces may be better served with invasive ventilation and are generally not candidates for NPPV.

Document inability to cooperate, need for tracheostomy/protected airway, or excessive secretions as reasons NPPV is contraindicated.
If full-face masks or other interfaces are used to accommodate bulbar weakness, document justification and clinical rationale.

Denial Risk

Insufficient RCT evidence for some etiologies

Recognize limits of evidence for some indications. Randomized controlled trial (RCT) evidence is strong for COPD exacerbations but limited or lacking for many other etiologies of acute respiratory failure and other conditions; coverage for such uses may be denied or require additional documentation.

RCT-level evidence supports NIV for COPD and cardiogenic pulmonary edema; evidence is weak or lacking for asthma, pneumonia, acute lung injury, and immunocompromised populations — anticipate higher denial risk without robust justification.

Note

Coverage vs benefits

Coverage determinations are clinical guidance and do not alter member contract terms. Always reconcile policy-based medical necessity findings with the member’s benefit plan — a medical-necessity determination does not guarantee payment if the service is excluded by contract.

Check plan exclusions, prior authorization requirements, benefit maximums, and DME supplier rules before authorizing or dispensing equipment.

Documentation Required

Required clinical documentation for medical necessity

Required clinical documentation for medical necessity must be supplied with authorization requests and maintained in the medical record. Include specific tests and measurements that justify device selection and continued coverage.

Arterial blood gas results (awake and, when indicated, during sleep or immediately on awakening).
Sleep study reports (PSG or appropriate HST) with AHI/CAHI and oxygen desaturation data; document minimum recording times and event counts when applicable.
Pulmonary function tests (FVC, FEV1/FVC), maximal inspiratory pressure (MIP) when relevant, and documentation of prior therapies tried (oxygen, CPAP, bronchodilators, weight loss).

Documentation Required

Follow-up and documentation

Follow-up and documentation requirements: reassess the member and document adherence and benefit within the specified timeframe. Record objective measures that demonstrate ongoing need.

Physician reassessment within 60 days of initiation to assess adherence and clinical benefit (may include interview, awake ABG, overnight oximetry on therapy).
For continued coverage beyond initial months, document compliant use (average ≥4 hours per 24-hour period) and evidence of benefit.

Documentation Required

Postoperative ARF documentation

Postoperative acute respiratory failure (ARF) documentation expectations: when NPPV is used for postoperative hypoxemic respiratory failure, document that hypoxemia was refractory to or unsuitable for supplemental oxygen and justify NPPV as medically necessary.

Document indications, prior oxygen therapy attempts, physiologic measures, and reason NPPV was chosen over other therapies.
Include operative and postoperative course details supporting the need for noninvasive ventilation.

Documentation Required

Sleep study documentation standards

Sleep study documentation standards must be met for diagnosis and device payment. Ensure PSGs include required channels and that HSTs meet device-type criteria when used for non-OSA indications.

PSG must include sleep staging (EEG 1–4 leads, EOG, submental EMG), airflow, respiratory effort, and oximetry; for non-OSA indications PSGs must be facility-based.
HSTs (Types II–IV or validated alternative) are acceptable only if the device monitors sufficient channels and is validated for the intended diagnosis (CSA/CompSA evaluation often requires facility PSG).

Documentation Required

Documentation & policy history

Maintain documentation of policy history and any plan-specific clinical bulletin used in decision-making. Cite the applicable policy version and date when submitting prior authorization requests or appeals.

Include the policy number (0452), effective date (09/15/2000), and most recent review date when relevant.
Retain copies of plan-level prior authorization responses and any clinical bulletins relied upon.

Step Therapy

Step requirement for bilevel PAP in COPD

Step therapy requirements for bilevel PAP in COPD: a trial of bilevel PAP without a backup rate feature is required before a device with a backup rate will be approved, except where immediate backup is clinically justified and documented per policy criteria.

A backup-rate bilevel device may be approved if PaCO2 worsens ≥7 mm Hg compared to baseline AND PSG on the bilevel device without backup shows persistent desaturation not due to obstructive events (AHI <5), or after ≥60 days of compliant use if abnormalities persist.
Document the timing, physiologic comparisons, and PSG/sleep oximetry findings that motivated escalation.

Step Therapy

CPAP trial before NPPV for OSA

CPAP trial before NPPV for OSA: when OSA is the predominant disorder, a diagnostic PSG and a CPAP trial are expected prior to initiation of bilevel NPPV unless there is clear documentation that CPAP is contraindicated or previously unsuccessful.

If CPAP is tried and fails or is not tolerated, document the nature of intolerance and objective evidence supporting bilevel therapy.
Exceptions: formal sleep testing may be waived if the medical record provides sufficient evidence that OSA is not the primary cause of hypercapnia or nocturnal desaturation.

Step Therapy

Step-up from CPAP to BPAP in OHS

Step-up from CPAP to BPAP in OHS: initial management of obesity hypoventilation syndrome with CPAP is appropriate when coexisting OSA is present; if CPAP is insufficient, escalate to bilevel (BPAP) and document inadequate response to CPAP.

Document CPAP trial duration, adherence, and objective outcomes (PaCO2, oximetry, symptoms) to justify transition to BPAP.
If OHS without significant OSA, bilevel/BPAP may be used as first-line — document rationale.

Definitions and Diagnostic Terms

Noninvasive positive pressure respiratory assistance — definition and admin notes

Definition — NPPV (general)Administration of positive air pressure using a nasal and/or oral mask interface that creates a seal to avoid invasive airway access; assists insufficient respiratory efforts and treats sleep-associated hypoventilation

Typical interfacesNasal, oral, or facial masks serving as noninvasive interfaces

Distinction from invasive ventilationNPPV avoids invasive airway access (e.g., tracheostomy) and is intended for non-life-threatening intermittent support

Ventilator with noninvasive interface — definition and intended reserved uses

Definition — Ventilator with noninvasive interfaceA ventilator capable of noninvasive support reserved for severe neuromuscular, thoracic restrictive diseases, or chronic respiratory failure where interruption of support could lead to death (CMS-aligned)

Intended reserved usesUsed when interruption or failure of respiratory support would lead to imminent demise; distinguished from bilevel PAP for intermittent support

Policy stanceUse of ventilators for conditions appropriately managed with bilevel PAP devices is considered not medically necessary

Noninvasive positive pressure respiratory assistance (NPPV) — alternate definition entry

Alternate NPPV definition entryNoninvasive positive pressure respiratory assistance: positive air pressure via nasal/oral mask interface to assist insufficient respiratory effort and treat sleep-associated hypoventilation

Operational noteMay be applied in acute and chronic ventilatory failure; policy focuses on bilevel PAP ventilators

DME MAC perspectiveDefined consistent with Durable Medical Equipment Medicare Administrative Carrier guidance distinguishing noninvasive assistance from invasive ventilation

Clinically significant nocturnal hypoxemia — threshold definition

Clinically significant nocturnal hypoxemia definitionOxyhemoglobin saturation <= 88% for at least 5 minutes of nocturnal recording time (minimum 2 hours)

Use in policy criteriaServes as an objective physiologic criterion for qualification and for assessing need to upgrade device features

Measurement contextMeasured by PSG or HST while breathing member's usual FIO2 or prescribed oxygen (COPD: while on 2 LPM or prescribed FIO2)

Adaptive servo-ventilation (ASV) — definition

Adaptive servo-ventilation (ASV) definitionA bilevel PAP system with a backup rate feature that performs breath-to-breath analysis and automatically adjusts airflow to maintain target minute ventilation

Primary clinical application notedMost studies have investigated ASV for heart failure patients with central apnea or Cheyne-Stokes respiration

Functional characteristicAutomatic minute-ventilation targeting with dynamic adjustment of delivered airflow

Single breath nitrogen test (SBNT) — definition

Single breath nitrogen test (SBNT) definitionPulmonary function test using a single vital-capacity inspiration of 100% O2 and analysis of expired nitrogen concentration to assess ventilation distribution and closing volume

Key measurementsPhase III slope (should be <1.5%) and closing volume relative to functional residual capacity

Clinical utility noteSBNT has limited clinical value for early detection compared with other tests

Apnea-hypopnea index (AHI) — definition and scoring notes

Apnea-hypopnea index (AHI) definitionAverage number of apnea and hypopnea episodes per hour of sleep without use of a positive airway pressure device

Scoring note for short recordingsIf AHI is calculated from <2 hours of continuous sleep, total recorded events must be >=10 to allow extrapolation

Contextual useAHI used to diagnose OSA and to distinguish central vs obstructive events in CSA/CompSA criteria

Central sleep apnea (CSA) / Complex sleep apnea (CompSA) — diagnostic definition

Central Sleep Apnea (CSA) diagnostic definitionAHI > 5 with central events >50% of total and CAHI >= 5 plus symptoms (eg, sleepiness, awakenings, shortness of breath)

Complex Sleep Apnea (CompSA) definitionPersistence/emergence of central apneas/hypopneas during PAP titration after obstructive events are treated (obstructive AHI <5) meeting CSA thresholds

CAHI recording ruleIf CAHI calculated from <2 hours of sleep, total recorded events must be >=10

Type I–IV sleep tests — classification and description

Type I sleep testFacility-based polysomnography with EEG, EOG, EMG (sleep staging) plus airflow, respiratory effort, and oxygen saturation (full-night or split-night)

Type II deviceMonitors >=7 channels: EEG, EOG, EMG, ECG/heart rate, airflow, respiratory movement/effort, and oxygen saturation

Type III and IV devicesType III monitors >=4 channels (respiratory movement/effort, airflow, ECG/HR, SpO2); Type IV monitors >=3 channels including airflow

NPPV / Noninvasive positive pressure ventilation — general definition and modalities

NPPV / Noninvasive positive pressure ventilation — general definitionNoninvasive delivery of positive air pressure via nasal/oral/facial mask interfaces to assist spontaneous respiratory efforts for acute and chronic respiratory failure and sleep-disordered breathing

Modalities includedBilevel PAP devices (with or without backup), CPAP, adaptive servo-ventilation, and ventilators with noninvasive interfaces (when indicated)

Clinical usesUsed for chronic and acute ventilatory failure, sleep-associated hypoventilation, OHS, COPD (selective), CSA/CompSA, and certain postoperative or airway stenting situations

OpenPayer

Noninvasive Positive Pressure Ventilation

Coverage Criteria for NPPV

Coding and Billing

Provider Actions, Prior Authorization, and Documentation

Background and Scope

Definitions and Diagnostic Terms

Policy Revision History